Quest Diagnostics, Inc. (NYSE: DGX) reported Q2 EPS of $1.08, $0.02 better than the analyst estimate of $1.06. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.88 billion.

Quest Diagnostics, Inc. sees FY2014 EPS of $4.00-$4.10, versus prior guidance of $3.95-$4.15 and the consensus of $4.02. Full year 2014 revenues now expected to be up 2.5% to 3.5%, versus up 2% to 4% previously.

"Quest Diagnostics grew revenues 5% and increased EPS 2%, as we continued to make good progress executing our strategy, and as underlying trends improved for pricing and volume," said Steve Rusckowski, President and CEO. "We saw strong testing growth in infectious disease, prescription drug monitoring and general health and wellness, and launched our OncoVantage solid tumor cancer panel through an exclusive relationship with Memorial Sloan Kettering Cancer Center. We are on track to meet our commitments for 2014."

For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.